Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion
Background: ALK tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and largely improved the survival outcomes of patients with NSCLC harboring <i>ALK</i> rearrangements. Different ALK TKI compounds have demonstrated antitumor activity in these patients and are available in clinical...
Gorde:
| Egile Nagusiak: | , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI AG
2023-11-01
|
| Saila: | Current Oncology |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.mdpi.com/1718-7729/30/11/729 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|